Prosecution Insights
Last updated: November 04, 2026
Application No. 17/258,984

SYSTEMS AND METHODS OF PREPARING AND FORMING GELS FOR AT LEAST ONE OBJECT

Non-Final OA §103§112
Filed
Jan 08, 2021
Priority
Jul 10, 2018 — provisional 62/696,261 +2 more
Examiner
OGUNBIYI, OLUWATOSIN A
Art Unit
1645
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Applied LifeSciences and Systems, LLC
OA Round
6 (Non-Final)
64%
Grant Probability
Moderate
6-7
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
600 granted / 940 resolved
+3.8% vs TC avg
Strong +41% interview lift
Without
With
+41.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
48 currently pending
Career history
997
Total Applications
across all art units

Statute-Specific Performance

§101
6.1%
-33.9% vs TC avg
§103
28.2%
-11.8% vs TC avg
§102
21.6%
-18.4% vs TC avg
§112
29.8%
-10.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 940 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . The amendment filed 7/28/2026 has been entered. Claims 2, 13-20, and 27 have been cancelled. Claim 21 has been amended. Claims 1, 3-12, 21-24 and 28 are pending and are under examination. Claim Status Identifier: the status identifier for claim 22 is currently amended. However, there is no indication that the claim has been amended, and the claim will be treated as such. Allowability Withdrawn: The indicated allowability of claims 1, 3-12, 23-24 and 28 is withdrawn in view of the foreign patent literature cited in the information disclosure statement filed 6/2/2026. The foreign patent literature is Japanese patent document JPS63502186A. The United States Patent 5,147,648 which is in the same patent family as JPS63502186A will be relied upon for the rejection since it is in English. Information Disclosure Statement (IDS): The IDS filed 6/2/2026 have been considered and initialed copies are enclosed. New Claim Rejections Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1, 3-12, 21-26 and 28 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection. The claims are drawn to forming a gel at respective mucosa. This limitation was first introduced in the claims filed on 03/19/2025. However, the only mucosa disclosed in the specification and the provisional application is facial mucosa of a hatch or mucosa areas of a hatchling, namely the eyes, and/or beak. No other mucosa areas are disclosed such as nose, mouth, throat, urogenital areas and gastrointestinal tract including mucosa areas of other animals. Applicant can obviate this rejection by amending the claim towards the disclosed mucosa area of hatch or hatchling such as facial, eyes and the beak of the hatch or hatchling. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 25 and 26 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. The limitations of claims 25 and 26 are already found in claim 1, thus claim 25-26 fail to further limit the subject matter of claim 1. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim(s) 1, 4-7, 12 and 21-26 is/are rejected under 35 U.S.C. 103 as being unpatentable over Toro et al. US 20110268762 11-03-2011 cited in IDS and Bannert et al. US 5147648 09-15-1992 cited in IDS. Toro et al disclose mucosal administration immunogenic and vaccine compositions via spraying of avians. See under abstract. Toro et al disclose that spraying is a useful method for mass immunization of avians because it is both labor and time saving. Toro et al disclose that spraying chickens results in intraocular administration, a combination of multiple route (intranasal, intraocular, transdermal and oral administration. See paragraphs 175-176. Toro et al disclose that mass immunization of avians against several avian pathogens is crucial to prevent enormous economic loss, and to impede transmission of avian pathogens. See paragraph 17. Toro et al does not disclose the high throughput system of claim 1 and claim 21 and the high throughput method of claim 23. Bannert et al disclose that gels can be used to apply medication to the mucosa and allow them to take effect. Bannert et al disclose that such gels can contain various active substances and can be applied to the mucosa in the nose, mouth and throat. Bannert et al disclose that instead of using a finished gel, components which together are capable of forming a gel were applied to the mucosa and surprisingly, it was seen that good adhesiveness could be obtained from the gel which subsequently formed. Bannert et al disclose the two components capable of forming a gel are dissolved separately, the solutions are then applied one after the other. Bannert et al disclose that it is preferable that the two components be sprayed onto the mucosa. See paragraphs 1-9 under description. Bannert et al disclose that calcium salts together with alginic acid or its derivatives can be used to form the gel. See paragraphs 10-17 under description. Bannert et al disclose a system and method for forming a gel at respective mucosa for targeted surfaces of respective animals, comprising: A solution comprising the binding agent e.g. calcium carbonate is provided – this corresponds to a first vessel containing a binding agent in a first liquid solution; A solution comprising the gelling agent e.g. sodium alginate is provided - this corresponds to a second vessel containing a gelling agent in a second liquid solution; A sprayer comprising the first liquid solution – corresponds to a first delivery device in fluid communication with the first vessel, the first delivery device having a first delivery outlet; A sprayer comprising the second liquid solution – corresponds to a second delivery device in fluid communication with the second vessel, the second delivery device having a second delivery outlet; Wherein the system is configured to target a mucosa of a first animal -Barnett et al disclose the two solutions are sprayed directly onto the mucosa and a gel is formed at the mucosa by moving the first solution from the first vessel to the first delivery device outlet to create a first spray toward the targeted mucosa (first sprayer) and moving the second solution from the second vessel to the second delivery device outlet to create a second spray toward the targeted mucosa (first sprayer) i.e. the two solutions are sprayed onto the mucosa and they react on the mucosa to form a gel on the mucosa of the animal. See under description and claims. It would have been prima facie obvious to a person of ordinary skill in the art as of the effective filing date of the instant invention to have modified the method or system of mass vaccination of avians (high throughput) of Toro et al by using the system of Bannert et al to form a gel on the mucosa of the avians, wherein the gel comprises the medication or vaccine, thus resulting in the instant invention with a reasonable expectation of success. The motivation to do so is that Toro et al disclose that spraying is a useful method for mass immunization of avians because it is both labor and time saving and that spraying chickens result in intraocular administration, a combination of multiple route (intranasal, intraocular, transdermal and oral administration) and that mass immunization of avians against several avian pathogens is crucial to prevent enormous economic loss, and to impede transmission of avian pathogens and Bannert et al disclose that gels can be used to apply medication to the mucosa which allows the medication to take effect and Bannert et al disclose that such gels can contain various active substances and can be applied to the mucosa in the nose, mouth and throat. The mass vaccination system/method of the combination of Toro et al and Bannert would result in the targeting of respective mucosa of individual animals with the group of animals and form gels at the respective targeted mucosa so that gel formation is directed specifically at the respective mucosa of the individual animals in the group of animals being mass vaccinated. Claim(s) 3 and 10-11 is/are rejected under 35 U.S.C. 103 as being unpatentable over Toro et al. US 20110268762 11-0302011 cited in IDS and Bannert et al. US 5147648 09-15-1992 cited in IDS as applied claims 1, 4-7, 12 and 21-26 above further in view of Bhandari et al. WO 2009/062254 5/22/2009 cited previously. The combination of Toro et al and Bannert et al does not disclose that the binding agent is calcium chloride and wherein the calcium chloride is at a concentration from about 1% to about 5% and wherein the sodium alginate is present in a concentration from about 0.5% to about 5%. Bhandari et al disclose a system for forming a gel for a targeted surface (see p. 22 lines 24- 31 to page 23 lines 1-7 "coating") of object such as "actives" having application in industries such as food, agricultural, manufacturing, chemical, biochemical, cosmetic printing, wherein the actives are probiotics (a biologic or nutraceutical), microorganisms, viruses, dies or ink (for use in printing) , agricultural activities such as pesticides, herbicides, cosmeceuticals, medicine such as ibuprofen, gentamicin, vitamins, enzymes (see page 14 lines 1-15 corresponding to the limitation of claims 5 and 6), wherein the system comprises A first vessel containing a binding agent such as calcium chloride (page 11) in a first liquid solution -see figure 1 #34, p. 12 lines 7-11; A second vessel containing a gelling component (sodium alginate) in a second liquid solution - figure 1 #36, page 9 lines 5-7, page 10, p. 12 lines 7-11, p. 22 lines 11 lines 19-31, page 13); A second delivery device in fluid communication (fig. 1 #40) with the second vessel, the second delivery device having a second delivery device outlet (i.e. an atomizer fig. 1#30, page 11 lines 19-31, page 12); Wherein the system is configured to form a gel for a targeted surface i.e. the "active" of a first object by moving the first solution from the first vessel to the first atomizer to create a first spray, and moving the second solution from the second vessel to the second atomizer to create a second spray, so that the first and second solutions react only after being outputted from the first and second atomizers to form a gel ( see p. 6) for the targeted surface of the first object i.e. the active, and Wherein the system is further configured to continuously repeat the formation of a gel for targeted surfaces of additional objects -Bhandari et al disclose the process is operated in a continuous manner (page 5 lines 26-31). See figure 1-6. Claim 4: Bhandari et al disclose the active or product of interest is in the solution of the cross-linkable reagent or is in the solution of the cross-linking reagent -see page 12 lines 21-31 and page 13 lines 1-6. Bhandari et al disclose the active or product of interest is a vaccine. See p. 25 lines 24-27. Bhandari et al disclose the calcium chloride is present in a concentration of 1- 3%. Claim Bhandari et al disclose the sodium alginate is present in a concentration of 1- 3%. It would have been prima facie obvious to a person of ordinary skill in the art as of the effective filing date to the instant invention to have modified the method/system of the combination of Toro and Bannert by using calcium chloride as the calcium salt at a concentration of 1-3% and sodium alginate at a concentration of 1-3% as taught by Bhandari et al thus resulting in the instant invention with a reasonable expectation of success. The motivation to do so is that Bhandari et al disclose that gels can be formed with calcium chloride at a concentration of 1- 3% and sodium alginate at a concentration of 1- 3%. Claim(s) 8-9 and 28 is/are rejected under 35 U.S.C. 103 as being unpatentable over Toro et al. US 20110268762 11-0302011 cited in IDS and Bannert et al. US 5147648 09-15-1992 cited in IDS as applied claims 1, 4-7, 12 and 21-26 above further in view of Evans et al CZ164296A3 3-12-1997 cited previously. The combination of Toro et al and Bannert does not disclose the vaccine comprises oocysts, or sporocyst or a mixture thereof. Evans et al disclose vaccines for chickens comprising oocysts or sporocysts. The vaccines are useful for vaccinating against Eimeria. See whole document. It would have been prima facie obvious to a person of ordinary skill in the art as of the effective filing date of the instant invention to have modified the system or method of the combination of Toro et al and Bannert by using the system/method to deliver an Eimeria vaccine to chickens by including the vaccine in the first or second solution, thus resulting in the instant invention with a reasonable expectation of success. The motivation to do so is that Toro et al disclose that mass immunization of avians against several avian pathogens is crucial to prevent enormous economic loss, and to impede transmission of avian pathogens and the system of the combination of Toro et al and Bannert would have enabled the mass vaccination of chickens against Eimeria. Status of Claims Claims 1, 3-12, 21-26 and 28 are rejected. Any inquiry concerning this communication or earlier communications from the examiner should be directed to OLUWATOSIN A OGUNBIYI whose telephone number is (571)272-9939. The examiner can normally be reached IFP. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Allen can be reached at 5712703497. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /OLUWATOSIN A OGUNBIYI/Primary Examiner, Art Unit 1645
Read full office action

Prosecution Timeline

Show 12 earlier events
Sep 02, 2025
Response after Non-Final Action
Sep 05, 2025
Examiner Interview (Telephonic)
Dec 16, 2025
Request for Continued Examination
Dec 17, 2025
Response after Non-Final Action
Jan 30, 2026
Non-Final Rejection mailed — §103, §112
Jun 01, 2026
Response Filed
Jul 28, 2026
Response Filed
Oct 09, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778990
Composition for Babies and Infants for Improving Memory Ability in Childhood
4y 9m to grant Granted Nov 03, 2026
Patent 12767703
ANTIBODY BINDING SPECIFICALLY TO SARS-COV-2 S PROTEIN OR ANTIGEN-BINDING FRAGMENT THEREOF, BISPECIFIC ANTIBODY, AND USES THEREOF
2y 12m to grant Granted Oct 20, 2026
Patent 12758598
COMPOSITION FOR IMPROVING INFLAMMATION OF BRAIN TISSUE
3y 4m to grant Granted Oct 13, 2026
Patent 12752000
IMMUNOSTIMULATORY ADJUVANTS
3y 9m to grant Granted Oct 06, 2026
Patent 12734201
PROBIOTIC COMPOSITION FOR THE TREATMENT OF COVID-19
3y 1m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

6-7
Expected OA Rounds
64%
Grant Probability
99%
With Interview (+41.1%)
2y 11m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 940 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month